Abstract
Bariatric surgery (BS) is a potential treatment option for patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity. These patients are also at substantial risk of developing cardiovascular events and associated mortality. We aimed to assess if BS could reduce major adverse cardiovascular events (MACE) and mortality and improve long-term survival. Using the TriNetX data, adult patients (>18 years) with the diagnosis of MASLD, obesity (i.e. body mass index [BMI] ≥35kg/m2), and pre-existing coronary artery disease (CAD) between January 1, 2005, to December 31, 2022, were included. Patients with a BS were compared to those with no history of BS. Primary outcomes were the incidence of MACE, heart failure, cerebrovascular events, and coronary artery procedures or surgeries at years 1, 3, 5, 7, and 10. The secondary outcome was all-cause mortality at years 1, 3, 5, 7, and 10. We performed 1:1 propensity score matching (PSM), sensitivity analysis, and survival analysis. After PSM, both groups had a total of 1038 patients. At year 1, BS patients had a significantly lower incidence of MACE (HR=0.56, 95% CI, 0.39-0.80), cerebrovascular disease (HR=0.62, 95% CI, 0.46-0.82), and coronary artery procedures and surgeries (HR=0.65, 95% CI, 0.42-0.98). Similarly, at 3, 5, 7, and 10, BS patients had a significantly lower incidence of MACE, heart failure, cerebrovascular disease, and coronary artery procedures and surgeries. BS patients had significantly lower 3, 5, 7, 10-year all-cause mortality. Sensitivity analysis confirmed these findings. BS in patients with MASLD, obesity, and pre-existing CAD can considerably reduce the risk of recurring cardiovascular events and markedly improve survival immediately within the first year of BS and can persist long-term, even a decade after BS.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call